190 related articles for article (PubMed ID: 38522483)
1. Microbiome interactions with different risk factors in development of myocardial infarction.
Bijla M; Saini SK; Pathak AK; Bharadwaj KP; Sukhavasi K; Patil A; Saini D; Yadav R; Singh S; Leeuwenburgh C; Kumar P
Exp Gerontol; 2024 May; 189():112409. PubMed ID: 38522483
[TBL] [Abstract][Full Text] [Related]
2. The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation.
Rahman MM; Islam F; -Or-Rashid MH; Mamun AA; Rahaman MS; Islam MM; Meem AFK; Sutradhar PR; Mitra S; Mimi AA; Emran TB; Fatimawali ; Idroes R; Tallei TE; Ahmed M; Cavalu S
Front Cell Infect Microbiol; 2022; 12():903570. PubMed ID: 35795187
[TBL] [Abstract][Full Text] [Related]
3. Potential Association of the Oral Microbiome with Trimethylamine N-Oxide Quantification in Mexican Patients with Myocardial Infarction.
Hernández-Ruiz P; Escalona Montaño AR; Amezcua-Guerra LM; González-Pacheco H; Niccolai E; Amedei A; Aguirre-García MM
Mediators Inflamm; 2024; 2024():3985731. PubMed ID: 38415052
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota and cardiovascular diseases axis.
Moldovan DC; Ismaiel A; Fagoonee S; Pellicano R; Abenavoli L; Dumitrascu DL
Minerva Med; 2022 Feb; 113(1):189-199. PubMed ID: 33969961
[TBL] [Abstract][Full Text] [Related]
5. Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder.
Luqman A; Hassan A; Ullah M; Naseem S; Ullah M; Zhang L; Din AU; Ullah K; Ahmad W; Wang G
Front Immunol; 2024; 15():1321395. PubMed ID: 38343539
[TBL] [Abstract][Full Text] [Related]
6. Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review.
Dai Y; Shen Z; Khachatryan LG; Vadiyan DE; Karampoor S; Mirzaei R
Pathol Res Pract; 2023 Sep; 249():154740. PubMed ID: 37567034
[TBL] [Abstract][Full Text] [Related]
7. Update on gut microbiota in cardiovascular diseases.
Qian B; Zhang K; Li Y; Sun K
Front Cell Infect Microbiol; 2022; 12():1059349. PubMed ID: 36439214
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota and myocardial fibrosis.
Xu H; Yang F; Bao Z
Eur J Pharmacol; 2023 Feb; 940():175355. PubMed ID: 36309048
[TBL] [Abstract][Full Text] [Related]
9. Gut Microbiota and Cardiovascular Disease: Symbiosis Versus Dysbiosis.
Manolis AA; Manolis TA; Melita H; Manolis AS
Curr Med Chem; 2022; 29(23):4050-4077. PubMed ID: 34961453
[TBL] [Abstract][Full Text] [Related]
10. Microbiome and hypertension: where are we now?
Vallianou NG; Geladari E; Kounatidis D
J Cardiovasc Med (Hagerstown); 2020 Feb; 21(2):83-88. PubMed ID: 31809283
[TBL] [Abstract][Full Text] [Related]
11. The gut-immune axis during hypertension and cardiovascular diseases.
Dinakis E; O'Donnell JA; Marques FZ
Acta Physiol (Oxf); 2024 Jun; ():e14193. PubMed ID: 38899764
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease.
El Hage R; Al-Arawe N; Hinterseher I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768722
[TBL] [Abstract][Full Text] [Related]
13. Loss of Gut Microbiota Alters Immune System Composition and Cripples Postinfarction Cardiac Repair.
Tang TWH; Chen HC; Chen CY; Yen CYT; Lin CJ; Prajnamitra RP; Chen LL; Ruan SC; Lin JH; Lin PJ; Lu HH; Kuo CW; Chang CM; Hall AD; Vivas EI; Shui JW; Chen P; Hacker TA; Rey FE; Kamp TJ; Hsieh PCH
Circulation; 2019 Jan; 139(5):647-659. PubMed ID: 30586712
[TBL] [Abstract][Full Text] [Related]
14. Myocardial infarction and gut microbiota: An incidental connection.
Zununi Vahed S; Barzegari A; Zuluaga M; Letourneur D; Pavon-Djavid G
Pharmacol Res; 2018 Mar; 129():308-317. PubMed ID: 29133215
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiome mediates the protective effects of exercise after myocardial infarction.
Zhou Q; Deng J; Pan X; Meng D; Zhu Y; Bai Y; Shi C; Duan Y; Wang T; Li X; Sluijter JP; Xiao J
Microbiome; 2022 May; 10(1):82. PubMed ID: 35637497
[TBL] [Abstract][Full Text] [Related]
16. Impact of gut microbiota: How it could play roles beyond the digestive system on development of cardiovascular and renal diseases.
Suganya K; Son T; Kim KW; Koo BS
Microb Pathog; 2021 Mar; 152():104583. PubMed ID: 33164814
[TBL] [Abstract][Full Text] [Related]
17. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.
Zhen J; Zhou Z; He M; Han HX; Lv EH; Wen PB; Liu X; Wang YT; Cai XC; Tian JQ; Zhang MY; Xiao L; Kang XX
Front Endocrinol (Lausanne); 2023; 14():1085041. PubMed ID: 36824355
[TBL] [Abstract][Full Text] [Related]
18. Exosomes derived from human placental mesenchymal stem cells ameliorate myocardial infarction via anti-inflammation and restoring gut dysbiosis.
Yang L; Wang T; Zhang X; Zhang H; Yan N; Zhang G; Yan R; Li Y; Yu J; He J; Jia S; Wang H
BMC Cardiovasc Disord; 2022 Feb; 22(1):61. PubMed ID: 35172728
[TBL] [Abstract][Full Text] [Related]
19. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions.
Trøseid M; Andersen GØ; Broch K; Hov JR
EBioMedicine; 2020 Feb; 52():102649. PubMed ID: 32062353
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases.
Usman I; Anwar A; Shukla S; Pathak P
Cardiovasc Hematol Disord Drug Targets; 2024 Jun; ():. PubMed ID: 38879769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
